90Y-labetuzumab (90Y-hMN14)
/ Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 06, 2023
A Pilot Study of Pembrolizumab and Embolization or 90Y Radioembolization for Patients with Metastatic WellDifferentiated Neuroendocrine Tumors
(NANETS 2023)
- "Combination therapy with pembrolizumab and TAE or TARE did not lead to abscopal responses in a small group of patients with metastatic WD-NET."
Clinical
1 to 1
Of
1
Go to page
1